Related Experiment Video
Updated: Jan 21, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Apolipoprotein(a) Kinetics in Statin-Treated Patients With Elevated Plasma Lipoprotein(a) Concentration
Louis Ma1,2, Dick C Chan1,2, Esther M M Ooi1
1School of Biomedical Sciences, Faculty of Health and Medicine, University of Western Australia, Perth, Western Australia, Australia.
Insights
Elevated Lipoprotein(a) [Lp(a)] in statin-treated patients is due to increased production, not reduced clearance. This highlights the need for therapies targeting apolipoprotein(a) [apo(a)] synthesis to manage cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Pharmacology
Background:
- Lipoprotein(a) [Lp(a)] is a key cardiovascular risk factor, even in patients on statin therapy.
- Elevated Lp(a) levels are associated with increased cardiovascular disease risk.
- The kinetic basis for elevated Lp(a) in statin-treated patients requires elucidation.
Purpose of the Study:
- To compare the production rate (PR) and fractional catabolic rate (FCR) of apolipoprotein(a) [apo(a)] between statin-treated patients with and without elevated Lp(a).
- To investigate the kinetic factors contributing to high Lp(a) levels.
- To provide a rationale for targeted therapies.
Main Methods:
- Stable isotope techniques and compartmental modeling were used to study apo(a) kinetics.
- 14 patients with elevated Lp(a) and 15 with normal Lp(a) were included, all on statin treatment.
- Plasma apo(a) concentration was measured using liquid chromatography-mass spectrometry.
Main Results:
- Patients with elevated Lp(a) exhibited significantly higher plasma apo(a) concentration and PR compared to controls (P < 0.01).
- No significant difference in apo(a) FCR was observed between the groups.
- Plasma apo(a) concentration strongly correlated with apo(a) PR (r = 0.699 to 0.949), but not FCR.
Conclusions:
- Increased hepatic production of Lp(a) particles is the primary driver of elevated plasma Lp(a) in these patients.
- These findings support therapies aimed at reducing apo(a) synthesis and Lp(a) production.
- Understanding Lp(a) kinetics is crucial for developing effective cardiovascular disease prevention strategies.
Background:
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein‒like particle containing apolipoprotein(a) [apo(a)]. Patients with elevated Lp(a), even when treated with statins, are at increased risk of cardiovascular disease. We investigated the kinetic basis for elevated Lp(a) in these patients.
Objectives:
Apo(a) production rate (PR) and fractional catabolic rate (FCR) were compared between statin-treated patients with and without elevated Lp(a).
Methods:
The kinetics of apo(a) were investigated in 14 patients with elevated Lp(a) and 15 patients with normal Lp(a) levels matched for age, sex, and body mass index using stable isotope techniques and compartmental modeling. All 29 patients were on background statin treatment. Plasma apo(a) concentration was measured using liquid chromatography-mass spectrometry.
Results:
The plasma concentration and PR of apo(a) were significantly higher in patients with elevated Lp(a) than in patients with normal Lp(a) concentration (all P < 0.01). The FCR of apo(a) was not significantly different between the groups. In univariate analysis, plasma concentration of apo(a) was significantly associated with apo(a) PR in both patient groups (r = 0.699 and r = 0.949, respectively; all P < 0.01). There was no significant association between plasma apo(a) concentration and FCR in either of the groups (r = 0.160 and r = -0.137, respectively).
Conclusion:
Elevated plasma Lp(a) concentration is a consequence of increased hepatic production of Lp(a) particles in these patients. Our findings provide a kinetic rationale for the use of therapies that target the synthesis of apo(a) and production of Lp(a) particles in patients with elevated Lp(a).
Related Concept Videos
Freezing Point Depression and Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
Enzyme Kinetics
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...
Kinetic Energy
Kinetic Molecular Theory: Molecular Velocities, Temperature, and Kinetic Energy
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Elevation of Intermediate Points on Vertical Curves

